Acute phase plasma proteins are altered by electroconvulsive stimulation. (December 2014)

• Record Type: Journal Article
• Authors: Glaviano, Antonino; O'Donovan, Sinead M; Ryan, Karen; O'Mara, Shane; Dunn, Michael J; McLoughlin, Declan M
• Is Part Of: Journal of psychopharmacology. Volume 28:Number 12(2014:Dec.)
• Page Start: 1125
• Page End: 1134
• Publication Date: 2014-12
• Subjects: Animal model -- apolipoprotein -- biomarkers -- electroconvulsive stimulation -- electroconvulsive therapy -- electroshock -- haptoglobin -- plasma -- protein profile -- repeated therapy; Psychopharmacology -- Periodicals; 615.78
• DOI: 10.1177/0269881114552742
• Languages: English
• ISSNs: 0269-8811

Abstract

Electroconvulsive therapy (ECT) is an effective antidepressant treatment, but its molecular mechanisms of action remain to be fully elucidated. To better understand the effects of ECT, we conducted a proteomic study to characterize global changes in plasma protein abundance induced by electroconvulsive stimulation (ECS) in the animal model equivalent of ECT. Male Sprague-Dawley rats were administered a single or repeat (10 sessions) course of ECS, and compared with sham-ECS administered animals. Quantitative differential protein expression analysis was performed, using 2-dimensional difference in gel electrophoresis (2D DiGE), on immunodepleted plasma. Proteins were selected for identification by liquid chromatography tandem mass spectrometry (LC-MS/MS): 150 protein spots were significantly altered following a single ECS and 178, following repeated ECS. In total, 18 proteins were identified by LC-MS/MS. Many of these were acute-phase response proteins, previously reported to be increased in depressed patients. Changes in the abundance of two proteins of interest were confirmed by other measures. Repeat ECS was found to significantly reduce plasma levels of haptoglobin and apolipoprotein A-IV, although these changes were no longer evident 4 weeks after the repeated ECS. Our results implicate the immune system-induced acute phase protein response in ECS action while identifying potential plasma biomarkers for ECS.